Will MEDRELEAF CORPORATION ORD (OTCMKTS:MEDFF) Run Out of Steam Soon? Short Interest is Up

February 15, 2018 - By Michael Pereira

The stock of MEDRELEAF CORPORATION ORD (OTCMKTS:MEDFF) registered an increase of 60.11% in short interest. MEDFF’s total short interest was 56,200 shares in February as published by FINRA. Its up 60.11% from 35,100 shares, reported previously. With 200,100 shares average volume, it will take short sellers 0 days to cover their MEDFF’s short positions.

The stock increased 5.06% or $0.8443 during the last trading session, reaching $17.5243. About 308,920 shares traded. MedReleaf Corp. (OTCMKTS:MEDFF) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

MedReleaf Corp. produces and sells cannabis pharmaceutical products in Canada. The company has market cap of $1.72 billion. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. It currently has negative earnings.

More notable recent MedReleaf Corp. (OTCMKTS:MEDFF) news were published by: Bloomberg.com which released: “MedReleaf Raises $75 Million in North America’s Biggest Pot IPO” on June 01, 2017, also Bloomberg.com with their article: “MedReleaf Worst Canadian Debut Since 2001 as Pot Stocks Wilt” published on June 07, 2017, Forbes.com published: “One Of Canada’s Largest Cannabis Producers, MedReleaf, Files To Go Public” on April 28, 2017. More interesting news about MedReleaf Corp. (OTCMKTS:MEDFF) were released by: Seekingalpha.com and their article: “MedReleaf Ready To Rumble: Positioned Well For Long-Term Growth” published on January 23, 2018 as well as Marketwired.com‘s news article titled: “MedReleaf Corp. Completes Initial Public Offering” with publication date: June 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: